MID-C – BIBA Medtech Insights

OrthoPediatrics buys ApiFix Ltd, developer of FDA-approved non-fusion scoliosis technology

OrthoPediatrics has acquired ApiFix, including its minimally invasive deformity correction (MID-C) system for non-fusion treatment of progressive adolescent idiopathic scoliosis, for 934,768 shares of OrthoPediatrics common stock and US$2 million in cash paid at closing, plus milestone payments and an earnout over a period of four years. A press release reports that ApiFix is [...]

ApiFix can commercialise its MID-C system for motion-preserving deformity treatment in the USA

ApiFix has received FDA approval, via a Humanitarian Device Exemption (HDE), to market the minimally invasive deformity correction system for the treatment of progressive adolescent idiopathic scoliosis. A press release reports that ApiFix’s MID-C technology is a posterior dynamic deformity correction system that enables surgeons to perform a unique treatment providing permanent curve correction [...]